Mesoblast
Mesoblast is a regenerative medicine company developing innovative therapies for unmet medical needs.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Mesoblast's stock with a target price of $22.50, indicating good growth potential.
Financial Health
Mesoblast is generating solid revenue and cash flow, indicating good financial health and growth potential.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MESO
MASH Drug Developers Could Attract M&A in 2025
Roche's $3.5 billion deal to acquire 89bio for its late-stage liver disease drug highlights the immense commercial potential seen in the MASH treatment landscape. This move could trigger a wave of investment and further acquisitions, benefiting other biotech firms with promising therapies for metabolic disorders.
Published: September 19, 2025
Explore BasketMASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: September 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Innovative cell therapies
Mesoblast’s allogeneic approach aims to offer off-the-shelf treatments that modulate inflammation, though clinical success is uncertain and timelines can be long.
Milestones drive value
Regulatory decisions and late-stage trial results tend to move the stock; this can create strong movement both up and down.
Commercial and funding risk
Potential partnerships could support commercialisation, but the company may also need further capital — a common risk for clinical-stage biotechs.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
